ARHGAP35

Across TCGA pan-cancer cohorts, ARHGAP35 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGAP35 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARHGAP35 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGAP35 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where ARHGAP35 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.496	0.852	<.001	29	view →
GBM	OS	Median	All	0.968	0.748	.001	18	view →
LUAD	OS	Tertile	III,IV	0.861	0.334	.004	12	view →
HNSC	DFS	Median	All	0.361	0.860	.022	6	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	4	view →
UCEC	OS	Median	II,III,IV	0.641	0.941	.048	4	view →
LSCC	DFS	Tertile	All	0.963	0.882	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARHGAP35–PDAC (DFS)

Open the PDAC breakdown →